Percutaneous coronary intervention (PCI) decreases ischemic complications of acute coronary syndromes. The benefits of PCI in stable ischemic heart disease (SIHD) depend on its effect on quality of life (QOL), including angina, physical activity, and emotional well‐being.
When considering treatment options for symptomatic SIHD, physicians should consider and provide objective data regarding QOL effects for each treatment strategy. QOL outcomes should be considered in clinical trials, appropriate use criteria, practice guidelines, and reimbursement policies for PCI.
All authors: James C. Blankenship, MD, MHCM, FSCAI; J. Jeffrey Marshall, MD, FSCAI; Duane S. Pinto, MD, MPH, FSCAI; Richard A. Lange, MD, MBA, FSCAI; Eric R. Bates, MD, FSCAI; Elizabeth M. Holper, MD, MPH, FSCAI; Cindy L. Grines, MD, MSCAI; and Charles E. Chambers, MD, MSCAI.
Other Guidance Documents
Evidence-based recommendations that promote optimal patient care based on current state-of-the-art science in interventional cardiology.